• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2011 Fiscal Year Final Research Report

Study for the efficacy of'Metronomic chemotherapy' agains the gynecological cancers

Research Project

  • PDF
Project/Area Number 21592135
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionKyushu University

Principal Investigator

KOBAYASHI Hiroaki  九州大学, 医学研究院, 准教授 (70260700)

Project Period (FY) 2009 – 2011
Keywords婦人科腫瘍学 / 婦人科がん / メトロノミック化学療法
Research Abstract

Recently proposed' Metronomic chemotherapy' is the new therapy using repeated administration of low dose anticancer drugs to induce' tumor dormancy state' without serious side effects against even drug-resistant tumors, based on the background that vascular endothelial cells are reproducibly susceptible to even small amount of drugs. In this study, we conducted animal experiments and clinical trials to evaluate the efficacy of metronomic chemotherapy on the gynecologic cancers. Mice bearing a paclitaxel-resistant tumor of human ovarian cancer were treated by divided-low dose or single-high dose administration of paclitaxel, and the tumor growth was more inhibited in the mice treated by the former. The toxicity was obviously mild in the mice administered by the divided-low dose. Therefore, metronomic chemotherapy seemed to be able to inhibit the tumor growth in spite of a mild side effect against drug-resistant tumors. As this reason, the divided-low dose administration of paclitaxel was found to inhibit neovascularization better than the single-high dose administration, by the experiment to evaluate the neovascularity into Matrigel. Similar results were obtained by the other anticancer drugs of docetaxel and irinotecan. Based on the theory of metronomic chemotherapy, we conducted a clinical trial of the tumor dormancy therapy by the divided-low dose anticancer drugs administered with an individualized maximum repeatable dose(iMRD). After IRB approval until now, 42 ovarian and 29 cervical cancer patients of intractable recurred cases were introduced to this study, and good QOL and relatively long TTP(time to progression) were obtained. Although the number of case is small and the follow-up period is short, the efficacy of tumor dormancy therapy applied by metronomic chemotherapy was suggested.

  • Research Products

    (11 results)

All 2011 2010 2009

All Journal Article (4 results) (of which Peer Reviewed: 4 results) Presentation (7 results)

  • [Journal Article] Nuclear localizationof E-cadherin but not beta-catenin in human ovarian granulosa cell tumors and normal ovarian follicles and ovarian stroma2011

    • Author(s)
      Ohishi Y, Oda Y, Kurihara S, Kaku T, Kobayashi H, Wake N, Tsuneyoshi M
    • Journal Title

      Histopathology

      Volume: 58(3) Pages: 423-432

    • Peer Reviewed
  • [Journal Article] Cytoplasmic and stromal expression of laminin? 2 chain correlates with infiltrative invasion in ovarian mucinous neoplasms of gastro-intestinaltype2010

    • Author(s)
      Okuma E, Ohishi Y, Oda Y, Aishima S, Kurihara S, Nishimura I, Yasunaga M, Kobayashi H, Wake N, Tsuneyoshi M
    • Journal Title

      Oncol Rep

      Volume: 24(6) Pages: 1569-1576

    • Peer Reviewed
  • [Journal Article] Low-dose mithramycin exerts its anticancer effect via the p53 Signaling pathway and synergizes with nutlin-3 ingynecologic cancers2010

    • Author(s)
      Ohgami T, Kato K, Kobayashi H, Sonoda K, Inoue T, Yamaguchi S, Yoneda T, Wake N
    • Journal Title

      Cancer Sci

      Volume: 101(6) Pages: 1387-1395

    • Peer Reviewed
  • [Journal Article] The level of RCAS1 expression is inversely correlated with the number of vitamin-positive stromal cells in epithelialovarian cancer2009

    • Author(s)
      Sonoda, K, Miyamoto S, Kobayashi H, Ogawa S, Okugawa K, Taniguchi S, Wake N
    • Journal Title

      Int J Gynecol Cancer

      Volume: 19(5) Pages: 838-843

    • Peer Reviewed
  • [Presentation] プラチナ感受性再発卵巣がんに対する、標準的化学療法は?~プラチナ感受性再発卵巣がんに対する臨床の実際~2011

    • Author(s)
      小林裕明
    • Organizer
      第49回日本癌治療学会(招請講演)
    • Place of Presentation
      名古屋市
    • Year and Date
      2011-10-28
  • [Presentation] Metronomic chemotherapy理論に基づくがん休眠療法と術後補助療法2011

    • Author(s)
      小林裕明
    • Organizer
      第4回北摂骨盤底疾患研究会(特別講演)
    • Place of Presentation
      大阪市
    • Year and Date
      2011-09-10
  • [Presentation] Metronomic chemotherapy理論に基づくがん休眠療法と維持化学療法2011

    • Author(s)
      小林裕明
    • Organizer
      第24回関越DIF研究会(特別講演)
    • Place of Presentation
      東京
    • Year and Date
      2011-02-19
  • [Presentation] 難治性再発の子宮頸がんおよび卵巣がんに対するイリノテカンのエビデンスとトライアル2010

    • Author(s)
      小林裕明
    • Organizer
      第49回日本婦人科腫瘍学会学術講演会(招請講演)
    • Place of Presentation
      佐賀
    • Year and Date
      2010-12-04
  • [Presentation] 難治性再発卵巣がんに対するがん休眠状態を目指したテーラード化学療法の基礎的臨床的研究2010

    • Author(s)
      小林裕明
    • Organizer
      第49回日本婦人科腫瘍学会学術講演会(公募研究助成報告)
    • Place of Presentation
      佐賀
    • Year and Date
      2010-12-04
  • [Presentation] Metronomic Chemotherapy理論に基づく術後補助療法の有用性2010

    • Author(s)
      小林裕明
    • Organizer
      第4回北関東婦人科がん臨床試験コンソーシアム教育セミナー(招請講演)
    • Place of Presentation
      浦和市
    • Year and Date
      2010-05-13
  • [Presentation] 卵巣癌治療の新たな展開-10年後を見据えて-難治性再発卵巣癌に対する治療:病巣の進行を抑制し共存延命を目指すがん休眠化学療法2009

    • Author(s)
      小林裕明
    • Organizer
      第47回日本癌治療学会
    • Place of Presentation
      横浜
    • Year and Date
      2009-10-24

URL: 

Published: 2013-07-31  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi